Medical Oncology
Physician insights on cancer treatment protocols, immunotherapy, targeted therapies, and clinical trial updates.
Recent Discussions
For patients with newly diagnosed VTE on IV heparin planned for transition to DOAC, would you start at the loading or maintenance DOAC dose?
Agree with Dr. @Dr. First Last. In the clinical trials that led to rivaroxaban and apixaban approval, many patients had 2 days of injected anticoagulant first to arrive at successful outcomes leading to DOAC approval. I suggest IV heparin until hemodynamically normal (for PE), sq LMWH for a dose or ...
For patients with newly diagnosed VTE on IV heparin planned for transition to DOAC, would you start at the loading or maintenance DOAC dose?
Agree with Dr. @Dr. First Last. In the clinical trials that led to rivaroxaban and apixaban approval, many patients had 2 days of injected anticoagulant first to arrive at successful outcomes leading to DOAC approval. I suggest IV heparin until hemodynamically normal (for PE), sq LMWH for a dose or ...
In stage 4 hilar cholangiocarcinoma, after stenting the biliary tree is there value in radiating the hilar area in addition to systemic therapy so as to maintain patency of the biliary system for a longer period of time or do you depend on the systemic therapy and the stenting alone?
In the setting of metastatic hilar cholangiocarcinoma, biliary patency is one issue but the greater issue is colonization of the biliary tree with gut flora that leads to repeated bouts of cholangitis, and progressive biliary sclerosis that happens regardless of the use of radiation. These patients ...
How do you utilize genomic testing in HR positive breast cancer to make recommendations regarding the duration of endocrine therapy?
Extending HRT from 5 to 10 years, whether with a SERM or an AI, reduces the risk of recurrence and new breast cancers. BUT the benefit is small and the toxicity is not inconsequential, making decisions challenging. Oncotype was developed to identify patients who would benefit from chemotherapy. As c...
Between KEYNOTE A-18 and INTERLACE, for which patients would you recommend using one protocol over another?
We currently favor A-18 for stage III disease (clinical or node-positive). A-18 had a more modern RT technique both for EBRT and brachytherapy while in INTERLACE, 60% had a prescription to point A for brachytherapy. In comparison with the EMBRACE 3D brachytherapy series, pelvic recurrence rate seems...
Would you use MammaPrint in patients with triple-negative or HER2-positive breast cancer based on the results from the MINDACT trial?
The MINDACT data from the 2016 NEJM article has a lot of detail, in particular Table 1, which gives the number of subjects in each risk group sorted by clinicopathologic features. There were 638 Her2 positive subjects out of 6693 total, or 9.5%. Of these, 501 (7.5% of total) were ER positive and Her...
Do you consider ADT intensification with enzalutamide or abiraterone in patients receiving adjuvant radiation with ADT?
I agree with Dr. @Dr. First Last.One thing to note is ~3% of RADICALS, for example, included pT3b and high grade disease, and almost no patients in the ART vs SRT trials had N+ disease. Was largely GS7 and pT3a population and not the very high risk patients that select surgeons choose to operate on....
How does your surveillance for DLBCL change given the new role of CAR-T in 2nd line treatment?
There were at least 2 large studies from Europe showing that surveillance imaging for lymphoma patients in remission after completion of upfront treatments don’t improve survival (regardless of histology). I don’t usually get any imaging for DLBCL in remission after the end of treatment imaging. Pos...
How are you deciding between available third line therapies for post-transplant relapsed DLBCL?
If a patient relapses after an autologous stem cell transplant and is a candidate for CAR T-cell therapy, I would proceed with CAR T-cell therapy given longer follow up compared to bispecific antibodies, and thus a portion of the patient can achieve a durable complete response. For patients that rel...
How does your surveillance for DLBCL change given the new role of CAR-T in 2nd line treatment?
There were at least 2 large studies from Europe showing that surveillance imaging for lymphoma patients in remission after completion of upfront treatments don’t improve survival (regardless of histology). I don’t usually get any imaging for DLBCL in remission after the end of treatment imaging. Pos...